Prognostic prediction and treatment strategy in hepatocellular carcinoma

Hepatology

Volumn 35, Issue 3, 2002, Pages 519-524

  Bruix, Jordi ^a   Llovet, Josep M ^a,b  

^a UNIVERSITY OF BARCELONA   (Spain)

^b Proyecto IMME UCV FONACIT   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CISPLATIN; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL;

ARTIFICIAL EMBOLISM; DISEASE COURSE; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 0036189111     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1053/jhep.2002.32089     Document Type: Article

References (50)

1. Rising incidence of hepatocellular carcinoma in the United States
2. Estimating the world cancer burden: GLOBOCAN 2000
3. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL Conference
4. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: An evidence-based approach
5. Hepatocellular carcinoma in Italian patients with cirrhosis
6. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: A cost-effectiveness analysis
7. Prognosis of hepatocellular carcinoma: The BCLC staging classification
8. Natural history of untreated nonsurgical hepatocellular carcinoma: Rationale for the design and evaluation of therapeutic trials
9. Natural history of inoperable hepatocellular carcinoma: Estrogen receptors' status in the tumor is the strongest prognostic factor for survival
10. Trends in survival of patients with hepatocellular carcinoma between 1997 and 1996 in United States
11. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients
12. A new prognostic classification for predicting survival in patients with hepatocellular carcinoma
13. Prospective validation of the CLIP score: A new prognostic system for patients with cirrhosis and hepatocellular carcinoma
14. Surgical resection versus transplantation for early hepatocellular carcinoma: Clues for the best strategy
15. Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure
16. An analysis of 412 cases of hepatocellular carcinoma at a Western center
17. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: Resection versus transplantation
18. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan
19. Treatment strategy for small hepatocellular carcinoma: Comparison of long-term results after percutaneous ethanol injection therapy and surgical resection
20. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma
21. Effects of long-term postoperative interferon-alpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized control trial
22. Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: A prospective randomised trial
23. Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: A randomised trail
24. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis
25. Liver transplantation for treatment of small hepatocellular carcinoma: The TNM classification does not have prognostic power
26. Liver transplantation for hepatocellular carcinoma
27. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis
28. Liver transplantation for hepatocellular carcinoma: Expansion of tumor size limits does not adversely impact survival
29. Right lobe living donor liver transplantation: A review
30. Adult-to-adult living-donor liver transplantation: A critical analysis
31. Liver donor liver transplantation for early hepatocellular carcinoma: A cost-effectiveness persepctive
32. Liver transplantation for hepatic and biliary mailgnancy
33. Cost-effectiveness of adjuvant therapy for hepatocellular carcinoma before liver transplantation
34. Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma
35. Hepatocellular carcinoma and cirrhosis in 746 patients: Long-term results of percutaneous ethanol injection
36. Radiofrequency ablation in the treatment of hepatocellular carcinoma- a clinical viewpoint
37. Small hepatocellular carcinoma: Treatment with radio-frequency ablation versus ethanol injection
38. Increased risk of tumor seeding after radiofrequency thermal ablation for single hepatocellular carcinoma
39. Hepatocellular carcinoma: Radio-frequency ablation of medium and large lesions
40. Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma- a randomized controlled trial
41. A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma
42. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma
43. Randomised trial of targeted chemotherapy with lipiodol and 5-epidoxorubicin compared with symptomatic treatment for hepatoma
44. Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: Results of a randomized, controlled trial in a single institution
45. Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: A multicenter randomized trial
46. Embolization with or without chemotherapy versus symptomatic treatment in patients with unresectable hepatocellular carcinoma
47. Treatment of hepatocellular carcinoma with tamoxifen: A double-blind placebo-controlled trial in 120 patients
48. Tamoxifen in treatment of hepatocellular carcinoma: A randomised controlled trial
49. Chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of pooled data